fair enough - I think manufacturing shouldn’t be an issue. It clearly has the advantage in that area. I think it’s more the logistics and supply chain of the drug that will make it tricky to commercialise. It has a longer half life but it is still time sensitive.
Personally, it’s not something that I know too much about but that would definitely be something Pharma companies will look for as well as the manufacturing.
Research/Valuation, page-5
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.93 |
Change
0.330(7.17%) |
Mkt cap ! $1.508B | |||
| Open | High | Low | Value | Volume |
| $4.68 | $4.95 | $4.60 | $3.984M | 828.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 592 | $4.92 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.93 | 2860 | 1 |
View Market Depth
| Last trade - 11.47am 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$4.85 |
Change
0.330 ( 6.27 %) |
||||
| Open | High | Low | Volume | ||
| $4.67 | $4.95 | $4.60 | 60761 | ||
| Last updated 12.07pm 30/05/2024 ? | |||||
| CU6 (ASX) Chart |